Marinus Pharmaceuticals, Inc. (MRNS)

NASDAQ: MRNS · IEX Real-Time Price · USD
4.69
-0.07 (-1.47%)
Dec 2, 2022 4:00 PM EST - Market closed
-1.47%
Market Cap 227.16M
Revenue (ttm) 19.84M
Net Income (ttm) -15.47M
Shares Out 37.20M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 158,537
Open 4.69
Previous Close 4.76
Day's Range 4.52 - 4.71
52-Week Range 3.97 - 13.15
Beta 1.15
Analysts Buy
Price Target 26.86 (+472.7%)
Earnings Date Nov 8, 2022

About MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for... [Read more]

Industry Pharmaceuticals
IPO Date Jul 31, 2014
Employees 113
Stock Exchange NASDAQ
Ticker Symbol MRNS
Full Company Profile

Financial Performance

In 2021, MRNS's revenue was $15.35 million, an increase of 793.19% compared to the previous year's $1.72 million. Losses were -$98.78 million, 46.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for MRNS stock is "Buy." The 12-month stock price forecast is 26.86, which is an increase of 472.71% from the latest price.

Price Target
$26.86
(472.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

4 days ago - Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

2 weeks ago - Business Wire

Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that ...

2 weeks ago - Business Wire

Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commerciali...

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

2 weeks ago - Business Wire

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Marinus Pharmaceuticals Announces Proposed Public Offering

RADNOR, Pa.

3 weeks ago - Business Wire

Marinus Pharmaceuticals (MRNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

7 Sizzling Stocks That Are Oblivious to the Manic Market

It's a scientific reality that people don't operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out o...

Other symbols: MFGSLDBTRUP
1 month ago - InvestorPlace

Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

1 month ago - Business Wire

Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Developme...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

2 months ago - Business Wire

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

2 months ago - Business Wire

Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

3 months ago - Business Wire

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

3 months ago - Business Wire

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 D...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder

4 months ago - Business Wire

Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk

Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.

4 months ago - Zacks Investment Research

Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million

4 months ago - Business Wire

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022

4 months ago - Business Wire

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Statu...

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

5 months ago - Business Wire

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

6 months ago - Business Wire

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research